Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Siglec-G represses DAMP-mediated effects on T cells
Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy
Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy
View: Text | PDF
Research Article Immunology Transplantation

Siglec-G represses DAMP-mediated effects on T cells

  • Text
  • PDF
Abstract

The role of negative regulators or suppressors of the damage-associated molecular pattern–mediated (DAMP-mediated) stimulation of innate immune responses is being increasingly appreciated. However, the presence and function of suppressors of DAMP-mediated effects on T cells, and whether they can be targeted to mitigate T cell–dependent immunopathology remain unknown. Sialic acid–binding immunoglobulin-like lectin G (Siglec-G) is a negative regulator of DAMP-mediated responses in innate immune cells, but its T cell–autonomous role is unknown. Utilizing loss-of-function–based (genetic knockout) and gain-of-function–based (agonist) approaches, we demonstrate that in the presence of certain DAMPs, Siglec-G suppressed in vitro and in vivo T cell responses. We also demonstrate that its T cell–autonomous role is critical for modulating the severity of the T cell–mediated immunopathology, graft-versus-host disease (GVHD). Enhancing the Siglec-G signaling in donor T cells with its agonist, a CD24Fc fusion protein, ameliorated GVHD while preserving sufficient graft-versus-tumor (GVT) effects in vivo. Collectively, these data demonstrate that Siglec-G is a potentially novel negative regulator of T cell responses, which can be targeted to mitigate GVHD.

Authors

Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy

×

Figure 3

Absence of Siglec-G on donor T cells exacerbates GVHD.

Options: View larger image (or click on image) Download as PowerPoint
Absence of Siglec-G on donor T cells exacerbates GVHD.
(A–E) BALB/c anim...
(A–E) BALB/c animals received 8.5 Gy on day –1 and were transplanted with 0.75 × 106 to 2.0 × 106 CD90.2+ splenic T cells from either syngeneic BALB/c or allogeneic MHC-mismatched B6 WT or B6 Siglec-G–/– animals along with 5 × 106 T cell–depleted bone marrow (TCD-BM) cells from either BALB/c or B6 donors. (A) Overall survival of allogeneic bone marrow transplantation (allo-BMT) with donor T cells, 0.75 × 106 (n = 24–26 per group). Pooled from 5 independent experiments. (B) Overall survival of allo-BMT with donor T cells, 2 × 106 (n = 5–10 per group). Pooled from 2 independent experiments. Kaplan-Meier method (A and B), *P < 0.05, when B6 versus Siglec-G–/– animals were compared. (C and D) Representative figures and histopathological graft-versus-host disease (GVHD) score in liver (C) and gastrointestinal (GI) tracts (small and large intestine) (D) at day 14 after allo-BMT (n = 5–10 per group, pooled from 2 experiments). *P < 0.05 by unpaired t test. (E–G) BALB/b and B6D2F1 animals were used as recipients and received either 8.5 Gy (BALB/b) or 11 Gy (B6D2F1) on day –1 and 4 × 106 (BALB/b) and 3 × 106 (B6D2F1) CD90.2+ T cells along with 5 × 106 TCD-BM cells from either syngeneic or allogeneic donors. (E) Overall survival in MHC-matched multiple minor antigens–mismatched B6→BALB/b model. n = 4–10 per group. Pooled from 2 independent experiments. Kaplan-Meier method, *P < 0.05 when B6 WT versus B6 Siglec-G–/– animals were compared. (F and G) Overall survival (F) and GVHD clinical score on day 7 (G) in MHC-mismatched haploidentical B6→B6D2F1 model. n = 10–27 per group. Pooled from 4 independent experiments. Kaplan-Meier method (F), *P < 0.05. Unpaired t test (G), ***P < 0.001, when B6 WT versus B6 Siglec-G–/– animals were compared. Data are shown as the mean ± SEM. (H) Survival of nonirradiated GVHD model. Recipient B6D2F1 animals received 50 × 106 whole splenocytes from either syngeneic B6D2F1 or allogeneic MHC-mismatched B6 WT or B6 Siglec-G–/– donors. n = 4–16 per group, pooled from 3 experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts